Idiopathic interstitial pneumonia

This study looks at the long-term safety of an inhaled medication called treprostinil for people with fibrotic lung diseases like idiopathic pulmonary fibrosis. About 1,850 adults who completed a prior related study will take the drug and be monitored for side effects. The goal i…

This phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.

This Phase 2 trial tests an oral drug called buloxibutid in 378 people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Over 52 weeks, researchers compare two doses of buloxibutid against a placebo to see if it can slow lung function decline. The study is double…

This study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…

This phase 2 trial tests whether an experimental drug called DWN12088 can safely slow the decline in lung function for people with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. About 102 adults aged 40 and older with stable IPF will be randomly assigne…

This phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. T…

This Phase 2 trial tests whether anlotinib, a drug currently used for cancer, can help people with idiopathic pulmonary fibrosis (IPF) or progressive fibrosis-interstitial lung disease. The study involves 30 adults aged 40-85 and measures changes in lung function over 52 weeks. P…

This study is developing a new way to treat pulmonary fibrosis, a condition where the lungs become scarred and stiff. The approach uses tiny particles called liposomes, coated with hyaluronic acid, to deliver drugs directly to the cells that cause scarring. The research is being …

This trial tests an investigational drug called CAL101 in 150 adults with idiopathic pulmonary fibrosis, a disease that scars the lungs and makes breathing harder. Participants receive monthly IV infusions of CAL101 or a placebo for 6 months. The goal is to see if CAL101 can prev…

This study tests an experimental tablet called HEC585 in 270 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. Participants receive either HEC585, a placebo (dummy pill), or an active comparator (Pirfenidone) to see if HEC…

This study tests a drug called axatilimab in 145 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal is to see if the drug can slow down the decline in lung function over 26 weeks compared to a placebo. Participants w…

This study tests an experimental drug called BMS-986278 in 1255 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. The goal is to see if the drug can slow the decline in lung function and is safe to take. Participants will receive ei…

This phase 2 trial tests an experimental drug called ENV-101 (taladegib) in 213 adults with idiopathic pulmonary fibrosis, a disease that causes lung scarring and makes breathing harder. Participants take either the drug or a placebo daily for several months. The main goal is to …

This early-stage study tests whether atezolizumab, a drug used for cancer, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. About 24 adults aged 50 and older with confirmed IPF will receive the drug. Research…

This early-stage study tests whether a person's own lung stem cells, grown from a small biopsy and given through an IV, are safe for treating idiopathic pulmonary fibrosis (IPF). Twenty-four adults with IPF will receive either a low or high dose of stem cells or standard care. Th…

This study aimed to test whether giving antibody-rich plasma from recovered COVID-19 patients could help hospitalized adults with pneumonia caused by the virus. The trial was withdrawn before any participants were enrolled, so no data was collected. The approach was based on the …

This phase 2 trial tests a new drug called LYT-100 (deupirfenidone) in 240 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing difficulty. Participants receive either LYT-100, the existing drug pirfenidone, or a placebo. The main goa…

This study tests a fast point-of-care PCR test (Spotfire) that quickly identifies whether a respiratory infection is caused by a virus. The goal is to give ER doctors results faster so they can avoid prescribing antibiotics when they won't help. The trial enrolls 200 adults with …

This study tests whether using a portable oxygen concentrator (a lightweight, battery-powered device) during walking or exercise helps people with interstitial lung disease (ILD) or COPD feel less breathless and be more active in their daily lives. Twenty-four participants will t…

This study looks at whether training one leg at a time on a bike can help people with idiopathic pulmonary fibrosis (IPF) exercise longer. IPF makes it hard to breathe, so using fewer muscles may allow a better workout. The trial will compare one-legged cycling to the usual two-l…

This pilot study tests whether home-based or video-supervised exercise programs are acceptable and helpful for people with chronic lung diseases like IPF, sarcoidosis, bronchiectasis, asthma, and other interstitial lung diseases. Fifty participants will be randomly assigned to on…

This study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future the…

Researchers are assembling a large group of adults with idiopathic pulmonary fibrosis (IPF), a progressive lung disease, to support future patient-centered studies. The team will combine electronic health records with patient-reported outcomes from clinics at several academic med…

This study looks at lung tissue from 80 people with pulmonary fibrosis to find unique genetic markers linked to scarring. By analyzing gene activity, researchers hope to better understand the disease and pave the way for new diagnostic tools and treatments. Participants must be 1…

This study tests whether a radioactive tracer called 68Ga-FAPi-46 can light up areas of scarring (fibrosis) in the lungs of people with interstitial lung disease. Participants receive the tracer and undergo a PET/CT scan to see where it collects. The goal is to understand how the…

This study looks for biological markers in blood and lung samples from people with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. The goal is to find markers that can predict how the disease will progress and to group patients into subtypes. Researchers…

This study at Duke University tests whether a special MRI scan using inhaled xenon gas can detect changes in lung function over time in people with progressive pulmonary fibrosis. Sixty adults with various types of lung scarring will have MRI scans before starting anti-fibrotic m…

This study looks at whether air samplers placed in homes can detect viruses that cause colds and flu, and how that compares to standard nasal swabs. About 422 students and their families will participate. The goal is to better understand how respiratory viruses spread through hou…

This study looks at how things in the environment and at work might affect people with interstitial lung diseases (a group of lung conditions). Researchers will ask 1,000 adults with a new diagnosis about their exposures to things like pollution, chemicals, and dust. The goal is …

This study follows 250 Italian adults with genetic forms of pulmonary fibrosis to see how their lung function changes over time. Researchers will track breathing tests and compare patients who receive immune-modulating drugs with those who do not. The goal is to understand how in…

This study follows 1,423 adults with idiopathic pulmonary fibrosis (IPF) for two years to learn how the disease progresses naturally. Researchers will track events like sudden worsening, hospital stays, and deaths. The goal is to better understand IPF patterns, not to test a new …

This study compares new, less invasive ways to collect samples for respiratory virus testing—like a nasal wash or saliva—against the standard deep nose swab. Researchers want to see if these gentler methods work just as well and cause less pain. About 1,000 adults in the emergenc…

This study places a rapid testing device in primary care clinics to help doctors quickly identify whether a cold-like illness is caused by a virus or bacteria. About 8,000 adults with symptoms like cough or runny nose will get a nasal swab, with results in 15 minutes. The goal is…

This registry is following 867 people with idiopathic interstitial pneumonias (IIPs), a group of rare lung diseases. The goal is to learn how these diseases behave over time, how they are diagnosed, and what treatments doctors currently use. No new drugs or procedures are being t…

This study looks at whether a molecule called miR200 in the blood can help detect idiopathic pulmonary fibrosis (IPF), a lung-scarring disease, at an early stage. Researchers will compare miR200 levels in 450 people: those with IPF, those with other lung diseases, and healthy vol…

This study observes 100 adults with idiopathic pulmonary fibrosis (IPF) who are taking the drug nintedanib. The goal is to understand who is more likely to get diarrhea as a side effect and to see if lowering the dose helps. Researchers will track diarrhea severity and how dose c…

This study is testing whether a questionnaire originally designed for COPD patients can be adapted to measure self-care in people with idiopathic pulmonary fibrosis (IPF). Researchers will enroll 156 adults with IPF to see if the tool accurately captures how well patients manage …